Basic Information
| LncRNA/CircRNA Name | LINCRNA-p21 |
| Synonyms | TP53COR1, TRP53COR1, linc-p21, lincRNA-p21 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | B-cell lymphoma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot etc. |
| Sample | B cell lymphoma tissues, DLBCL cell lines (SU-DHL-2, OCI-LY-3, OCILY-10, SU-DHL-4, OCI-LY-7) |
| Expression Pattern | down-regulated |
| Function Description | We found that lincRNA-p21 levels were markedly decreased in DLBCL tissues compared with normal. Its expression level was significantly correlated with Ann Arbor stages, B symptoms, performance status, IPI score and serum LDH. Moreover, patients with high levels of LincRNA-p21 expression had a favorable overall survival and progression-free survival. Furthermore, ectopic expression of lincRNA-p21 inhibited cell proliferation, arrested cycle progression and modulated cyclin D1, CDK4 and p21 expression in DLBCL cell lines. These results demonstrated lincRNA-p21 can be identified as a potential novel prognostic biomarker for prognosis in DLBCL and regulate cell proliferation and cycle in vitro |
| Pubmed ID | 26475621 |
| Year | 2015 |
| Title | LincRNA-p21 predicts favorable clinical outcome and impairs tumorigenesis in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy |
External Links
| Links for LINCRNA-p21 | GenBank HGNC NONCODE |
| Links for B-cell lymphoma | OMIM COSMIC |